home / stock / ucbjy / ucbjy news

UCBJY News and Press, UCB S.A. ADR From 11/08/19

Stock Information
Company Name: UCB S.A. ADR
Stock Symbol: UCBJY
Market: OTC
Menu
UCBJY UCBJY Quote UCBJY Short UCBJY News UCBJY Articles UCBJY Message Board
Get UCBJY Alerts

News, Short Squeeze, Breakout and More Instantly...
UCBJY - UCB Presents New Data From Rheumatology Portfolio Addressing Unmet Needs in Axial Spondyloarthritis, Psoriatic Arthritis and Lupus at 2019 ACR/ARP

BRUSSELS , Nov. 8, 2019 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced important new rheumatology data being presented on CIMZIA ® (certolizumab pegol) and investigational molecules bimekizumab and dapirolizumab pegol at the 2019 American College of Rheumat...
UCBJY - EVENITY® (romosozumab) Receives Positive CHMP Opinion for the Treatment of Severe Osteoporosis in Postmenopausal Women at High Risk of Fracture

BRUSSELS and THOUSAND OAKS, California , Oct. 18, 2019 /PRNewswire/ -- UCB (Euronext Brussels: UCB) and Amgen (NASDAQ: AMGN) today announced that following a re-examination procedure, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), ...

UCBJY - EVENITY® (Romosozumab) Receives Positive CHMP Opinion For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture

THOUSAND OAKS, Calif. and BRUSSELS , Oct. 17, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced that following a re-examination procedure, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has ad...

UCBJY - Bimekizumab Phase 3 Psoriasis Study Meets All Endpoints, Achieving Significantly Greater Efficacy Versus Placebo and Ustekinumab

BRUSSELS , Oct. 17, 2019 /PRNewswire/ -- Regulated Information - Inside Information - UCB, a global biopharmaceutical company, today announced positive results from BE VIVID, the first of three Phase 3 studies evaluating the efficacy and safety of bimekizumab, an IL-17A and IL-17F inhib...
UCBJY - UCB Agrees to Acquire Ra Pharmaceuticals: Joining Forces to Improve Treatment Options for People Living With Myasthenia Gravis and Other Rare Diseases

- Will enhance UCB's leadership potential in myasthenia gravis by adding zilucoplan , a peptide inhibitor of complement component 5 (C5) currently in phase 3, to the UCB pipeline alongside to UCB's rozanolixizumab , an FcRn targeting antibody also in phase 3 - Will enrich UCB's pipeline;...

UCBJY - Experts Consider Osteoporosis to Be a Silent Epidemic Which Is Neglected and Under Addressed, According to New Survey Released Today

- Osteoporosis is estimated to affect 200 million people worldwide 1  and results in a fracture every 3 seconds 2  yet a new survey reveals bone specialists in Europe think its impact is not fully recognised 3   - Specialists (82%) believe osteoporosis is a silent...

UCBJY - UCB Half Year Report 2019: UCB's Strong Performance Enables Continued Investment Into Future Growth Drivers

BRUSSELS , July 25, 2019 /PRNewswire/ -- – Regulated information – Revenue reached € 2.3 billion (+2%, +4% CER 1 ) net sales increased to € 2.2 billion (+3%, +5% CER – adjusted 2  +11%, +7% CER) Underlying profitability (rEBITDA 3 ) was &#x...
UCBJY - Rigel: Competitors And Collaborators

Rigel Pharmaceuticals' ( RIGL ) Tavalisse, launched in mid-2018, is experiencing sales growth but competitors exist that could potentially reduce peak sales. RIGL's partnered pipeline provides a source of potentially good news to offset any bad news regarding advances from RIGL's competitors...

UCBJY - Amgen and UCB Provide Regulatory Update on Status of EVENITY(TM) (romosozumab) in the EU

THOUSAND OAKS, Calif. and BRUSSELS , June 27, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced that the companies have been informed the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted...

UCBJY - UCB's Key Pipeline Molecule Bimekizumab Demonstrated Improved Outcomes for Ankylosing Spondylitis Patients

BRUSSELS , June 14, 2019 /PRNewswire/ -- UCB, a global biopharmaceutical company, announced new Phase 2b data on the company's key pipeline molecule, bimekizumab – a novel humanized monoclonal IgG1 antibody that potently and selectively neutralizes both IL-17A and IL-17F ...
Previous 10 Next 10